{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:41:38Z","timestamp":1760758898082,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.suronc.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T02:40:59Z","timestamp":1541731259000},"page":"57-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Cascales-Campos","family":"Pedro Antonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f3mez-Ruiz","family":"\u00c1lvaro Jes\u00fas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Elena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonz\u00e1lez","family":"Alida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machado-Linde","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carbonell-L\u00f3pez del Castillo","family":"Guillermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parrilla","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2018.11.005_bib1","first-page":"1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.suronc.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1272\/jnms.67.5","article-title":"It's what the surgeon doesn't see that kills the patient","volume":"67","author":"Sugarbaker","year":"2000","journal-title":"J. Nippon Med. Sch."},{"key":"10.1016\/j.suronc.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2018.11.005_bib6","first-page":"1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.suronc.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00432-014-1692-5","article-title":"Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites","volume":"140","author":"Ba","year":"2014","journal-title":"J. Canc. Res. Clin. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","article-title":"Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study","volume":"21","author":"Brun","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","article-title":"Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer","volume":"22","author":"Ansaloni","year":"2012","journal-title":"Int. J. Gynecol. Canc."},{"key":"10.1016\/j.suronc.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.suronc.2018.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.suronc.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","article-title":"Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"10.1016\/j.suronc.2018.11.005_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.10.856","article-title":"Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer","volume":"202","author":"Ch\u00e9reau","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.suronc.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of peritoneal-surface malignancy: the surgeon's role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbeck's Arch. Surg."},{"key":"10.1016\/j.suronc.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jso.21169","article-title":"Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis","volume":"99","author":"Pelz","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.24406","article-title":"Re: the American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score","volume":"114","author":"Foster","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","article-title":"Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer. Is there any difference?","volume":"25","author":"Cascales-Campos","year":"2016","journal-title":"Surgical Oncology"},{"key":"10.1016\/j.suronc.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"10.1016\/j.suronc.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0021-7697(04)95334-3","article-title":"Management of malignant epithelial tumors of the ovary","volume":"141","author":"Pomel","year":"2004","journal-title":"J. Chir."},{"key":"10.1016\/j.suronc.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.3802\/jgo.2017.28.e48","article-title":"Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer","volume":"28","author":"Lim","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.suronc.2018.11.005_bib25","article-title":"Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome","volume":"12","author":"Yang","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.suronc.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/ejso.2002.1380","article-title":"Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer","volume":"29","author":"Tentes","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9990","key":"10.1016\/j.suronc.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"The Lancet"},{"issue":"15_suppl","key":"10.1016\/j.suronc.2018.11.005_bib29","article-title":"Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"J. Clin. Orthod."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096074041830197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096074041830197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:16:10Z","timestamp":1760757370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096074041830197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"alternative-id":["S096074041830197X"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2018.11.005","relation":{},"ISSN":["0960-7404"],"issn-type":[{"type":"print","value":"0960-7404"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}